Effects of sevelamer on the progression of vascular calcification in patients on chronic haemodialysis

被引:51
作者
Takei, Takashi [1 ]
Otsubo, Shigeru [1 ]
Uchida, Keiko [1 ]
Matsugami, Keiko [2 ]
Mimuro, Tomoko [2 ]
Kabaya, Takashi [2 ]
Akiba, Takashi [1 ]
Nitta, Kosaku [1 ]
机构
[1] Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Shinjuku Ku, Tokyo 1628666, Japan
[2] Minami Senju Hosp, Tokyo, Japan
来源
NEPHRON CLINICAL PRACTICE | 2008年 / 108卷 / 04期
关键词
haemodialysis; vascular calcification; sevelamer hydrochloride; phosphate binder; cholesterol; C-reactive protein;
D O I
10.1159/000127361
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background/Aim: Vascular calcification is thought to be associated with a high cardiovascular mortality rate in patients with end-stage renal disease. Control of hyperphosphataemia is important for the treatment of the vascular calcification. The aim of the present study was to evaluate the effects of sevelamer hydrochloride on the progression of aortic calcification in haemodialysis (HD) patients. Methods: 42 HD patients were studied in this study and divided into two groups (sevelamer vs. calcium). Sevelamer was added and titrated up to achieve serum P control for 6 months. The estimations of aortic calcification index (ACI) by abdominal computed tomography scans were performed twice in each patient. We compared the changes in serum calcium, phosphorus, intact parathyroid hormone, and lipids in two groups. Results: Serum phosphorus levels decreased significantly from 6.7 +/- 0.7 to 6.2 +/- 0.5 mg/dl with no changes in serum intact parathyroid hormone levels in the sevelamer group (p < 0.01), and increased from 6.5 +/- 1.0 to 6.7 +/- 1.1 mg/dl in the calcium group (p < 0.05). Serum calcium levels did not change in the sevelamer group and calcium group. The serum levels of total cholesterol decreased significantly from 158.5 +/- 20.7 to 146.2 +/- 24.1 mg/ dl (p = 0.024) and the low-density lipoprotein cholesterol level from 65.3 +/- 14.4 to 54.7 +/- 11.6 mg/ dl (p = 0.014) in the sevelamer group. Serum C-reactive protein decreased significantly from 0.14 +/- 0.13 to 0.08 +/- 0.11 mg/ dl in the sevelamer group (p = 0.038) and significantly increased (0.18 +/- 0.09 vs. 0.22 +/- 0.12 mg/ dl) in the calcium group (p = 0.042). The mean changes in ACl (Delta ACI) were 3.6 +/- 1.5% in the sevelamer group and 8.2 +/- 3.1% in the calcium group. Conclusions: Sevelamer allows a better serum phosphorus control compared with calcium-based phosphate binder and suppresses the progression of aortic calcification in HD patients. Copyright (C) 2008 S. Karger AG, Basel
引用
收藏
页码:C278 / C283
页数:6
相关论文
共 31 条
  • [1] Influence of lipid-lowering therapy on the progression of coronary artery calcification - A prospective evaluation
    Achenbach, S
    Ropers, D
    Pohle, K
    Leber, A
    Thilo, C
    Knez, A
    Menendez, T
    Maeffert, R
    Kusus, M
    Regenfus, M
    Bickel, A
    Haberl, R
    Steinbeck, G
    Moshage, W
    Daniel, WG
    [J]. CIRCULATION, 2002, 106 (09) : 1077 - 1082
  • [2] CARDIAC PATHOLOGY IN PATIENTS WITH END-STAGE RENAL-DISEASE MAINTAINED ON HEMODIALYSIS
    ANSARI, A
    KAUPKE, CJ
    VAZIRI, ND
    MILLER, R
    BARBARI, A
    [J]. INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1993, 16 (01) : 31 - 36
  • [3] A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients
    Bleyer, AJ
    Burke, SK
    Dillon, M
    Garrett, B
    Kant, KS
    Lynch, D
    Rahman, SN
    Schoenfeld, P
    Teitelbaum, I
    Zeig, S
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 33 (04) : 694 - 701
  • [4] Block GA, 2000, CLIN NEPHROL, V54, P318
  • [5] Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study
    Block, GA
    Hulbert-Shearon, TE
    Levin, NW
    Port, FK
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) : 607 - 617
  • [6] Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients
    Braun, J
    Oldendorf, M
    Moshage, W
    Heidler, R
    Zeitler, E
    Luft, FC
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) : 394 - 401
  • [7] Chertow GM, 1999, CLIN NEPHROL, V51, P18
  • [8] Poly[allylamine hydrochloride] (RenaGel): A noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure
    Chertow, GM
    Burke, SK
    Lazarus, JM
    Stenzel, KH
    Wombolt, D
    Goldberg, D
    Bonventre, JV
    Slatopolsky, E
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1997, 29 (01) : 66 - 71
  • [9] The effects of sevelamer and calcium acetate on proxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients
    Chertow, GM
    Raggi, P
    McCarthy, JT
    Schulman, G
    Silberzweig, J
    Kuhlik, A
    Goodman, WG
    Boulay, A
    Burke, SK
    Toto, RD
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 2003, 23 (05) : 307 - 314
  • [10] Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients
    Chertow, GM
    Burke, SK
    Dillon, MA
    Slatopolsky, E
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (12) : 2907 - 2914